BMRN BioMarin Pharmaceutical Inc.

+0  (0%)
Previous Close 90.17
Open 90.61
Price To book 5.63
Market Cap 15.60B
Shares 172,866,000
Volume 825,515
Short Ratio 6.44
Av. Daily Volume 1,031,810

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released July 2016. Update due in December 2016. Phase 2b to be initiated 2H 2017.
BMN 270
Hemophilia A
Phase 3 trial initiation announced December 12, 2016.
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. BLA filing to be filed 2Q 2017.
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children
  2. BioMarin to Host First Quarter 2017 Financial Results Conference Call and Webcast on Thursday, May 4 at 4:30pm ET
  3. Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
  4. 5 Drug Stocks That Could Be Big Winners this Earnings Season
  5. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : April 14, 2017
  6. The Hot Stock: Alexion Pharmaceuticals Climbs 3.3%
  7. BioMarin Announces Kuvan® (sapropterin dihydrochloride) Patent Challenge Settlement
  8. Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride
  9. 3 Stocks We'd Buy and Hold for the Next 20 Years
  10. Just How Much Is a Medical Miracle Worth?
  11. 4 FDA Decisions to Watch Out for in Apr 2017
  12. 4 Drug Stocks With Big News Coming in April
  13. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : March 30, 2017
  14. Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?
  15. Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
  16. Catalyst Pharmaceuticals Inc (CPRX): Here’s What’s Next
  17. Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
  18. Biotechs Leap On Trump's Calls For Innovation, Speedy FDA Approval
  19. Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
  20. BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017